Categories AlphaGraphs, Earnings, Health Care
Key highlights from Abbott Laboratories (ABT) Q1 2024 earnings results
Abbott Laboratories (NYSE: ABT) reported its first quarter 2024 earnings results today.
Total sales increased 2.2% year-over-year to $10 billion. Organic sales growth was 10.8%.
Net earnings decreased 7% to $1.22 billion, or $0.70 per share, compared to last year. Adjusted EPS decreased 5% to $0.98.
Abbott expects GAAP EPS of $3.25-3.40 and adjusted EPS of $4.55-4.70 for full-year 2024. The company projects GAAP EPS of $0.69-0.73 and adjusted EPS of $1.08-1.12 for the second quarter of 2024.
Prior performance
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training
INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues
Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came
Riding the AI wave, Nvidia looks set to stay on the high-growth path
After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on
